Figure 2From: Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia Individual fits to 16 patients. Patients 1 to 8 are slow monophasic, and patients 9 to 16 are fast biphasic. The asterisk (*) represents measurements below the limit of quantification of the assay.Back to article page